Navigation Links
FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Date:10/28/2010

MOUNTAIN VIEW, Calif., Oct. 28 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.  The application seeks the approval to market QNEXA as an oral, once-a-day formulation for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

The CRL included the following areas: clinical, labeling, REMS, safety update, and drug scheduling.

In the clinical section of the CRL, the FDA requested a comprehensive assessment of topiramate's and phentermine/topiramate's teratogenic potential. This will include a detailed plan and strategy to evaluate and mitigate the potential teratogenic risks in women of childbearing potential taking the drug for the treatment of obesity. In addition, the FDA asked VIVUS to provide evidence that the elevation in heart rate associated with phentermine/topiramate does not increase the risk for major adverse cardiovascular events.

The FDA requested that VIVUS formally submit the results from the already completed SEQUEL study (OB-305), a 52-week extension study for a subset of 675 patients who completed the previously reported 56-week CONQUER study. Top-line results from the two-year SEQUEL study were announced by VIVUS on September 21, 2010 and a final study report is being prepared for submission to the NDA.

The FDA reserved the right to comment further on proposed labeling. On REMS, the FDA requested that a discussion of an
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Sage Analytics ( www.sageanalytics.com ), the developers ... measurement systems, announced its sponsorship of the California Cannabis ... limited number of tickets are available for groups or ... cause while enjoying an open bar, buffet dinner and ... Francisco Bay at sunset. With the legislative ...
(Date:8/3/2015)... 2015 Global physiotherapy ... USD 24.7 billion by 2022, according to a ... prevalence of neurological and musculoskeletal disorders are expected ... forecast period. The presence of efficient and effective ... the technologies coupled with implementation of favorable government ...
(Date:8/3/2015)... Biosensors International Group, Ltd. ("Biosensors" or ... B20), a developer, manufacturer and marketer of innovative ... first fiscal quarter ended 30 June 2015 ("Q1 ... Developments: , Biosensors continued to ... driven by lower operating expenses and operational improvement. ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6
(Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... industry-defining contract lifecycle management solution, as well as announced the date of its ... speed and ease of contract management tasks as well as enhancements to the ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... disorders (TD) was first described about 40 years ago. ... (PA) and Thyroiditis on the basis of gastric and ... on this frequently overlooked association. , A research article ... World Journal of Gastroenterology investigates the overlooked association. A ...
... with the annual,HIMSS healthcare IT conference, RemoteScan Corporation,( ... new pricing of,its popular RemoteScan(R) software. RemoteScan makes ... software to scan directly into any,medical document management ... or Windows Terminal Services servers. In addition to ...
... week Citi-Mobile,launched a new mobile billboard campaign to ... generously donated their mobile,billboards to the National Autism ... family assistance, and cutting-edge,research., The mobile billboards ... the cities of Glendale and Burbank. Kevin Bartanian, ...
... heart disease, study finds , , WEDNESDAY, Feb. 27 (HealthDay News) ... and adolescents with normal blood sugar levels had elevated markers ... for both type 2 diabetes and cardiovascular disease. , Researchers ... 10 to 18. Of those, 17 were lean and 21 ...
... WASHINGTON, Feb. 27 Following is the daily,Black History ... WEDNESDAY, FEBRUARY 27: INCOME & HEALTH INSURANCE, ... Month. The progress,of any segment of the U.S. population ... financial health. Recent figures show that the annual median ...
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer ... that,it plans to release fourth quarter and full year ... 2008 before the market opens., The Company will ... ET to,discuss results. Listeners may access the call by ...
Cached Medicine News:Health News:Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease? 2Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2Health News:Overweight Hispanic Kids Show Early Markers for Diabetes 2Health News:American Oriental Bioengineering to Report Fourth Quarter and Full Year 2007 Financial Results 2